Good morning. My name is Marshall Fordyce, and I am Chief Executive Officer of Vera Therapeutics. I am very happy to welcome you to the Vera Therapeutics 2026 Annual Stockholders Meeting. The meeting will now officially come to order. The time is now 8:00 A.M. Pacific Time on Thursday, May 21st, and the polls are now open for voting on all matters to be presented. I want to thank you all for joining us. As you know, we are hosting today's meeting through a virtual online platform hosted by Broadridge. In addition to myself, we are joined by members of the board and executive team who are with us virtually today. Also in attendance are Katie Wechsler and Jared Denham of KPMG LLP, the company's independent registered public accounting firm, who are available to respond to appropriate questions as needed after the proposals have been described.
We will proceed with the formal business of the meeting in the order set forth in the notice of annual meeting and proxy statement. We will first present the 3 proposals submitted for approval by our board. We will take questions related to the proposals or any questions for the auditors after all of the proposals have been presented, after which we will announce the preliminary results of the voting. We will answer other appropriate questions after the formal business of the meeting has concluded. As I mentioned earlier, the polls are open for voting on all matters to be presented. Each share of Class A common stock is entitled to 1 vote. After I describe each item to be voted on, we will close the polls. We will not accept ballots, proxies, revocations, or changes after the closing of the polls.
If you have already submitted your vote by proxy and do not wish to change your vote, you do not need to vote now, and your shares will be voted as previously instructed. If you intend to vote and have not already done so, you must submit your vote online now in order for it to be counted. If you have not voted, I encourage you to vote online now. The rules of conduct for this meeting are posted on our virtual meeting page. In order to conduct an orderly meeting, we ask that you follow these rules. Stockholders who are attending this meeting with a valid 16-digit control number may submit questions for the Q&A portion of this meeting through the text box located on the virtual meeting screen.
We will try to answer questions submitted that are relevant to the proposals after all proposals have been described and answer other appropriate questions in accordance with the rules of conduct after formal business has concluded. Jane Wright-Mitchell will screen incoming questions and during the Q&A portion of the meeting will read relevant questions out loud before I, Jane, or Sean respond. Please submit your questions now to make sure they are received in a timely fashion for our review and response. Jane Wright-Mitchell will act as secretary for this meeting. Will the secretary please report at this time with respect to the mailing of the notice of the meeting?
I have an affidavit certifying that a notice of annual meeting of stockholders of the company was duly given to all Class A stockholders of record at the close of business on March 24th, 2026. A copy of the notice and affidavit will be filed with the records of this meeting.
At this time, I'd like to introduce Anne St. Martin of CT Hagberg LLC, who is present virtually. Ms. St. Martin has been appointed to act as inspector of election at this meeting. Ms. St. Martin has taken and subscribed the customary oath of office to execute her duties with strict impartiality. We will file this oath with the records of the meeting. Will the inspector of election please report at this time with respect to the existence of a quorum?
I can report that proxies have been received for a majority of the 71,713,905 shares of Class A common stock outstanding on the record date, which constitutes a quorum for the meeting today, and we may now carry out the official business of the meeting.
We will now proceed with the formal business of the meeting. After all of the proposals have been described, we will answer questions related to the proposals submitted online. As a reminder, we ask that any questions during this portion of the meeting pertain only to these proposals. There are 3 proposals to be considered by the stockholders at this meeting. The first item of business is the election of 3 Class II directors to serve until the company's 2029 annual meeting and until their successors are elected and qualified, or until there are earlier death, resignation, or removal. The nominees for Class II directors are Michael Morrissey, Patrick Enright, and James Myers.
The second item of business today is the ratification of the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the company for the fiscal year ending December 31, 2026. The third item of business today is the advisory vote on the compensation of the company's named executive officers, as described in the proxy statement. The stockholders have been asked to vote on an advisory basis on the following resolution. Resolved that the compensation paid to the company's named executive officers as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion, is hereby approved. That was the final proposal for today's meeting. We will now review if there are any questions submitted about the proposals or addressed to the auditors before we close the polls.
As a reminder, we will only review and answer questions at this time that pertain to the proposals. Jane, are there any questions at this time?
At this time, there are no questions.
Given that there are no questions, the time is now 8:07, and the polls are now closed for voting. May we have the preliminary results of the voting?
The preliminary report of the Inspector of Election covering the proposals presented at this meeting is as follows. The proposal to elect Michael Morrissey, Patrick Enright, and James Myers as Class II directors of the company is carried. The selection of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026 is ratified. The resolution concerning the advisory vote on the compensation of the company's named executive officers is approved.
We expect to report our final voting results on a current report on Form 8-K, to be filed with the SEC within four business days after the end of this meeting. This concludes the formal portion of today's meeting. We will now review if there are any questions submitted about appropriate topics separate from the proposals. Jane Wright-Mitchell, are there any additional appropriate questions?
At this time, there are no questions.
Thank you to my fellow board members, along with our management team and KPMG for participating in our annual meeting of stockholders, and thank you to all of our stockholders for your continued support of Vera Therapeutics.
This concludes today's meeting. You may now disconnect.